PharmaJet Needle-free System Selected for WHO Polio Immunization Campaign in Somalia
2024年6月27日 - 11:10PM
ビジネスワイヤ(英語)
- The campaign builds upon evidence from house-to-house
administration of Inactivated Poliovirus in Nigeria which
demonstrated needle-free, intradermal vaccine administration is
easy-to-use and can achieve high immunization coverage.
- Over a quarter million of PharmaJet’s needle-free intradermal
syringes have been provided to support this initiative.
- The house-to-house campaign is a collaboration of AFENET, WHO,
UNICEF, BMGF, GAVI and CDC.
PharmaJet®, a company that strives to improve the performance
and outcomes of injectables with its innovative delivery systems,
today announced that their Tropis® Intradermal (ID) Needle-free
System will be used in a house-to-house polio immunization
campaign. With an aim of significantly reducing the immunity gap
against type-2 poliovirus, the campaign will be conducted in two
rounds. In each round, children 4-59 months of age will receive the
needle-free polio vaccine and novel oral polio vaccine with a goal
of achieving 95% coverage. The campaign, a collaboration of the
African Field Epidemiology Network (AFENET), WHO, UNICEF, BMGF,
GAVI and CDC, is targeting over 170,000 children in 4 districts in
Banadir, Somalia.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240620727486/en/
The ongoing variant poliovirus outbreak, the longest running of
its kind, has paralyzed 38 children in Somalia. The most recent
evidence for human circulating vaccine-derived polio virus-2
(cVDPV2) was on 8th March 2024. In April, Somalia’s Minister of
Health and Human Services, His Excellency Dr Ali Haji Adam, and
high-level representatives of the Global Polio Eradication
Initiative (GPEI) met to review progress and further scale up
efforts to end the country’s 7-year variant poliovirus outbreak.
Through the Somalia Emergency Action Plan (SEAP 3), the country
will continue to work with humanitarian partners to reach about 1.5
million zero-dose children, most of whom live in the country’s
highly populated central and southern areas.1
The house-to-house, needle-free campaign in Somalia builds on
the positive results of a WHO-led pilot in Nigeria which
demonstrated that administering an injectable vaccine with Tropis
facilitates high coverage rates.2 Specifically, the field
evaluation found a majority of parents (94%) and health staff
members (93%) preferred needle-free injections over needle and
syringe administration. 87% of target group children received their
immunization during this campaign.2
PharmaJet’s Tropis System was previously deployed for polio
vaccinations in the Berbera Region of Somaliland where researchers
found needle-free administration of fIPV “had the potential to
reach many more children as it could be implemented faster than
other immunization methods.” High immunization coverage was
achieved due to preference for the use of intradermal needle-free
delivery in addition to other factors and the willingness of
parents to bring their children due to less invasive administration
using needle-free. Previously, vaccine teams using needle-free for
polio vaccine administration in Pakistan achieved 18.4% improvement
in mean coverage while 97.6% of vaccinators and 99.6% of caretakers
expressed a preference for needle-free over traditional needle and
syringe.3
“The PharmaJet team is very pleased to collaborate with AFENET,
WHO, UNICEF, BMGF, GAVI and CDC on this important campaign. Having
delivered over 10 million polio immunizations using needle-free in
Nigeria, Pakistan, and Somalia, we are very committed to the Global
Polio Eradication Initiative,” said Paul LaBarre, Vice President,
Global Business Development, PharmaJet. “In Somalia, we are eager
to build on previous house-to-house campaign experience that
demonstrates how needle-free enables vaccination teams to move
quickly and achieve high coverage without the burden of sharps
waste management and with reduced vaccine volume and cold chain
logistics.”
For more information about PharmaJet visit
https://pharmajet.com.
Refer to Instructions for Use to ensure safe
injections and to review risks.
1 Somalia’s health minister and partners plan to intensify
efforts to end 7-year variant poliovirus outbreak, UNICEF, April
16, 2024 2 Biya, Oladayo, et al., Notes from the Field:
House-to-House Campaign Administration of Inactivated Poliovirus
Vaccine – Sokoto State, Nigeria, November 2022; Weekly/ November
24, 2023/72 (47): 1290-1291 3 Daly, C et al, Needle-free injectors
for mass administration of fractional dose inactivated poliovirus
vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and
vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February,
2020, Pages 1893-1898.
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes
of injectables with our innovative delivery systems that better
activate the immune system. We are committed to helping our
partners realize their research and commercialization goals while
making an impact on public health. PharmaJet Precision Delivery
Systems™ can improve increased vaccine effectiveness, allow for a
preferred patient and caregiver experience, and offer a proven path
to commercialization. They are also safe, fast, and easy-to-use.
The Stratis® System has U.S. FDA 510(k) marketing clearance, CE
Mark, and WHO PQS certification to deliver medications and vaccines
either intramuscularly or subcutaneously. The Tropis System has CE
Mark and WHO PQS certification for intradermal injections. They are
both commercially available for global immunization programs. For
more information or if you are interested in partnering with
PharmaJet to improve the impact of your novel development program,
visit https://pharmajet.com or contact PharmaJet here. Follow us on
LinkedIn.
About the Global Polio Eradication Initiative
The Global Polio Eradication Initiative is a public-private
partnership led by national governments with six partners – the
World Health Organization (WHO), Rotary International, the US
Centers for Disease Control and Prevention (CDC), the United
Nations Children’s Fund (UNICEF), Bill & Melinda Gates
Foundation and Gavi, the vaccine alliance. Its goal is to eradicate
polio worldwide. The Polio Eradication Strategy 2022–2026 brings
integration into focus through two transformations of approach. The
first is a recognition that for polio eradication to succeed,
chronically low immunization coverage and demand-based refusals of
polio vaccines in key geographies and populations must be
addressed, for which integration provides targeted solutions. The
second is a revaluation of integration as a step towards the
long-term, sustainable transition of polio functions to other
health programs and national health systems as the world nears
polio eradication.
CDC/Role in Global Polio Eradication
The CDC plays a critical role in eradicating polio by providing
scientific leadership and guidance at the global, regional, and
country levels to implement evidence-based strategies to stop polio
worldwide. CDC engages with partners, countries, and communities to
deliver vaccines, detect cases, and respond to outbreaks
quickly.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620727486/en/
Nancy Lillie Nancy.Lillie@pharmajet.com 1-888-900-4321 Option
3